Arch Therapeutics Inc. (ARTH)
OTCQB OTCQB Primary Summary
ARTH Chart
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
SAWC Fall provides a venue to educate clinicians about AC5 Advanced Wound System, present case studies, and continue strategic meetings with wound care companies. SAWC Fall provides a venue to educate clinicians about AC5 Advanced Wound System, present case studies, and continue strategic meetings with wound care companies.
Arch Therapeutics Inc. Dividends
Arch Therapeutics Inc. Earnings
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 19 Aug 2024 Date | | - Cons. EPS | - EPS |
| 16 Aug 2024 Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 19 Aug 2024 Date | | - Cons. EPS | - EPS |
| 16 Aug 2024 Date | | - Cons. EPS | - EPS |
Arch Therapeutics Inc. (ARTH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arch Therapeutics Inc. ever had a stock split?
Arch Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Terrence W. Norchi M.D. CEO | OTCQB Exchange | US03939W1099 ISIN |
| United States Country | 8 Employees | - Last Dividend | 18 Jan 2023 Last Split | - IPO Date |
Overview
Arch Therapeutics, Inc., alongside its subsidiaries, positions itself within the United States as a pioneering entity in the biotechnology sector. The essence of its operations is encapsulated in the development and commercialization of innovative solutions derived from its proprietary AC5 self-assembling technology platform. This platform is heralded for its efficacy in arresting bleeding, managing leaks, and navigating the intricacies of wound care across a spectrum encompassing surgery, trauma, interventional procedures, and conditions borne out of disease. Having planted its roots in 2006, the company commands a strategic base in Framingham, Massachusetts, reflecting a blend of seasoned experience and locality which nurtures innovation.
Products and Services
- AC5 Advanced Wound System: This offering stands at the forefront of Arch Therapeutics' product suite, specifically tailored for skin application scenarios. It addresses the management of complex chronic wounds and acute surgical wounds, marking a significant stride in the realm of wound care and management. The AC5 Advanced Wound System epitomizes the company's commitment to bridging the gap between innovative technology and real-world clinical needs.
- AC5 Topical Hemostat: Operating in tandem with the advanced wound system, the AC5 Topical Hemostat carves its niche in the quick cessation of bleeding. Tailored for immediate application, this product champions the cause of efficiency and effectiveness in bleeding control, marking a pivotal milestone in surgical and trauma care scenarios.
- AC5-G for Gastrointestinal Endoscopic Procedures: Progressing beyond the skin, Arch Therapeutics ventures into the gastrointestinal domain with AC5-G. This product iteration is specifically designed for endoscopic procedures within the GI tract, indicating a versatile extension of the AC5 technology platform in addressing internal bleeding challenges encountered during endoscopic interventions.
- AC5-V and AC5 Surgical Hemostat: Further elaborating on the theme of versatility, the AC5-V along with the AC5 Surgical Hemostat underscore the company's foray into hemostasis within the body’s internal cavities. These products are earmarked for their pivotal role in surgical procedures, offering innovative solutions for internal hemostasis, thereby highlighting the adaptability and potential of the AC5 technology platform in catering to a broad spectrum of medical applications.
Contact Information
